ZymoGenetics Experiences a Biotech Disconnect
This article was originally published in RPM Report
Executive Summary
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.